Home › Compare › CISXF vs ABBV
CISXF yields 1.54% · ABBV yields 3.06%● Live data
📍 CISXF pulled ahead of the other in Year 5
Combined, CISXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CISXF + ABBV for your $10,000?
China Steel Corporation manufactures and sells steel products in Taiwan, Vietnam, Malaysia, China, India, and internationally. It offers steel plates primarily for use in construction structures, shipbuilding, bridge beams, oil country tabular goods, machine structures, pressure vessels, and in climate/corrosion-resistant steel plates; steel bars and wire rods for use in general and machine structures, cold forging, hot forging, hard drawn steel wires, and welding electrodes; and hot-rolled coils and sheets that are used in automobile chassis, bridge beams, construction, road guardrails, steel pipe, pressure vessels, and landscaping. The company also provides cold-rolled coils for use in automobile stamping parts and home electronics products; parts requiring high-level forming, such as automobile and scooter components; a variety of PSE and structural reinforcement parts; and products requiring surface coating treatment, such as painting, electroplating, and the application of adhesive surfaces. In addition, it offers mechanical, communications, and electrical engineering services; and generates solar power. The company was incorporated in 1971 and is headquartered in Kaohsiung, Taiwan.
Full CISXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.